Halozyme Therapeutics Files 2024 10-K

Ticker: HALO · Form: 10-K · Filed: Feb 18, 2025 · CIK: 1159036

Halozyme Therapeutics, Inc. 10-K Filing Summary
FieldDetail
CompanyHalozyme Therapeutics, Inc. (HALO)
Form Type10-K
Filed DateFeb 18, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, biotechnology

TL;DR

Halozyme dropped its 2024 10-K. Full financials and biz details inside.

AI Summary

Halozyme Therapeutics, Inc. filed its 2024 10-K on February 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in San Diego, CA, operates in the biological products sector. Key financial details and operational information for the fiscal year are presented in this comprehensive annual report.

Why It Matters

This filing provides investors and stakeholders with a detailed overview of Halozyme's financial performance, strategic initiatives, and risk factors for the fiscal year 2024, crucial for understanding the company's current standing and future outlook.

Risk Assessment

Risk Level: medium — As a biotechnology company, Halozyme faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • 2024 — Fiscal Year (Reporting period for the 10-K filing.)
  • 1231 — Fiscal Year End (Indicates the end date of the fiscal year reported.)

Key Players & Entities

  • HALOZYME THERAPEUTICS, INC. (company) — Filer
  • 0001159036-25-000010 (other) — Accession Number
  • 20241231 (date) — Conformed Period of Report
  • 20250218 (date) — Filed as of Date
  • San Diego, CA (location) — Business Address City, State
  • 2836 (other) — Standard Industrial Classification Code

FAQ

What is the primary business of Halozyme Therapeutics, Inc. as indicated by its SIC code?

Halozyme Therapeutics, Inc. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its SIC code 2836.

When was the 10-K filing for the fiscal year ending December 31, 2024, submitted?

The 10-K filing was submitted on February 18, 2025.

What is the company's principal business address?

The company's business address is 12390 El Camino Real, San Diego, CA 92130.

What is the SEC file number for Halozyme Therapeutics, Inc.?

The SEC file number for Halozyme Therapeutics, Inc. is 001-32335.

What was the company's former name before its name change in 2004?

Before March 12, 2004, the company's former name was HALOZYME THERAPEUTICS INC.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 18, 2025 regarding HALOZYME THERAPEUTICS, INC. (HALO).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.